Treatment with omalizumab for up to 1 year was associated with continued improvements in symptoms of chronic rhinosinusitis with nasal polyps.
An exhalation delivery system appears to more effectively apply topical steroids to nasal polyps located in the ostiomeatal complex.
Women with chronic cough in the United States and United Kingdom were more likely to have a higher number of cough triggers.
Because of the prevalence of behavioral health issues in elderly patients with asthma, appropriate behavioral health treatment may improve patient outcomes.
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Heart rate, respiratory rate, and oxygen saturation (SpO2) levels with percentile-based cutoffs can predict the risk of prolonged hospitalization in pediatric asthma exacerbations.
Adding reslizumab to mometasone furoate enhanced clinical benefits of the intranasal corticosteroid alone in patients with uncontrolled chronic rhinosinusitis with nasal polyps and peripheral eosinophilia.
Patients with asthma that is poorly controlled by ICS/LABA therapy may experience improvement in lung function with the addition of umeclidinium and/or doubling of the corticosteroid fluticasone furoate.
Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks